Pixelgen Technologies Welcomes Dr. Aaron Viny to Its Board
Pixelgen Technologies has recently reinforced its Scientific Advisory Board (SAB) by announcing the appointment of Dr. Aaron D. Viny, a prominent physician-scientist from Columbia University. His role is pivotal as the company expands its efforts in developing innovative therapies for blood diseases and cancer, areas where there remains a significant need for new treatment options.
Dr. Viny is noted for his cutting-edge research examining the three-dimensional structure of DNA within blood cancers, particularly acute myeloid leukemia. This intricate study is shaping the future of targeted therapies aimed at improving outcomes for patients who often have limited choices available to them. In a statement, Pixelgen CEO Simon Fredriksson expressed enthusiasm about Dr. Viny's addition to the team and highlighted the strategic importance of his expertise in advancing their high-capacity, single-cell protein-interactome technology.
At Columbia University, Dr. Viny serves as an assistant professor of medicine, focusing on critical areas such as clonal hematopoiesis, myelodysplastic syndrome, and various forms of leukemia. His extensive background includes a focus on utilizing animal models and advanced 3D genomic techniques to unravel the genetic complexities associated with these diseases. Such innovative research is crucial for the development of more effective and less toxic treatment modalities.
In his own words, Dr. Viny remarked about the capabilities of Pixelgen's Proximity Network Assay technology, which excels in revealing intricate cellular interactions involved in immune responses. This technology illuminates networks that contribute to disease and resistance, thus laying the groundwork for future advancements in diagnostics and cellular therapies. Dr. Viny is excited to collaborate with the Pixelgen team to enhance this vital technology further.
On the same day as the announcement, Dr. Viny is set to share insights at Pixelgen's inaugural User Group Meeting. His presentation is titled "Lighting the Path Beyond the Streetlight: Mapping Protein Proximity to Overcome AML Resistance," where he will delve into his groundbreaking work and the implications of Pixelgen's technology for the medical community.
Dr. Viny's expertise will complement existing board members' wealth of knowledge, which includes notable figures such as genomicist and entrepreneur Mostafa Ronaghi, Ph.D., as well as Emma Lundberg, Ph.D. from Stanford University, and Petter Brodin, Ph.D. from Imperial College London.
About Pixelgen Technologies
Pixelgen Technologies AB strives to revolutionize biological understanding at the molecular level. The company's vision is to unlock cellular functions through innovative technologies that reveal the protein interactomics of single cells with unparalleled resolution. Their patented Proximity Network Assay exemplifies this mission, delivering nanoscale spatial analysis of immune cell proteins at unprecedented capacity. This technology underpins the Pixelgen Proxiome Kit, aimed at transforming precision medicine.
Founded in 2020 by a dedicated team of innovators, Pixelgen is focused on producing a robust portfolio designed to propel advancements in immunology, hematology, and cellular therapies. Being venture-backed enables them to pursue their ambitious goals in medical science.
Contact Information
For corporate inquiries, please reach out to:
Annika Branting
+46 762-69 68 46
For media inquiries, please contact:
Susan Thomas
+1 (619) 540-9195
Frequently Asked Questions
What is the significance of Dr. Aaron Viny's appointment?
Dr. Viny's expertise will greatly enhance Pixelgen's scientific advancements, especially in developing therapies for blood diseases and cancers.
What technology is central to Pixelgen's research?
Pixelgen's Proximity Network Assay technology is crucial for uncovering complex interactions at the single-cell level, which is essential for targeted therapies.
Who else is on Pixelgen's Scientific Advisory Board?
The board includes renowned experts such as Mostafa Ronaghi, Ph.D., Emma Lundberg, Ph.D., and Petter Brodin, Ph.D.
What areas does Dr. Viny specialize in?
Dr. Viny specializes in clonal hematopoiesis, myelodysplastic syndrome, and acute myeloid leukemias.
What are Pixelgen's primary goals?
Pixelgen aims to transform understanding of cellular function and revolutionize treatment solutions through innovative and precise biotechnologies.
